BioWorld Science

Feb. 12, 2021

View Archived Issues

Regenxbio initiates phase I/II study of RGX-121 gene therapy

Read More

Tessa Therapeutics enrolling participants in phase II CHARIOT study of CD30.CAR-T therapy

Read More

Celon successfully completes phase Ia study of CPL-116

Read More

BenevolentAI begins first-in-human trial of BEN-2293 for atopic dermatitis

Read More

New cancer anorexia therapeutic target identified

Read More

Wistar Institute patents new antibacterials against Pseudomonas

Read More

Sinocelltech discloses new anti-VEGF antibodies

Read More

Amicus reports topline phase III data on AT-GAA for late-onset Pompe disease

Read More

FDA clears IND for trial of LYS-GM101 in GM1 gangliosidosis

Read More

Bristol Myers Squibb synthesizes IRAK-4 inhibitors

Read More

Harbin Boyicheng Biotechnology discloses new HER2-targeting nanobodies

Read More

Last patient completes final visit for NORSE THREE safety study of ONS-5010

Read More

Capella BioScience discovers anti-PD-L1 antibodies

Read More

Researchers describe activity of BNT-162b2 against SARS-CoV-2 mutations

Read More

Specialization improves synthetic circuits

Read More

Preclinical findings support the use of HMI-202 for treating MLD

Read More

InflaRx presents data from phase IIb SHINE study of vilobelimab

Read More

Data on HMI-203 from animal studies support its further development for treating MPS II

Read More

European Commission approves Ogluo to treat severe hypoglycemia

Read More

New phase I/II trial investigates JSP-191 in sickle cell disease

Read More

FDA approves Evkeeza for homozygous familial hypercholesterolemia

Read More

Tukysa approved in E.U. for HER2-positive locally advanced or metastatic breast cancer

Read More

AC Immune reports interim data from phase Ib/II study of anti-pTau vaccine candidate ACI-35.030

Read More

Spanish AEMPS approves CAR-T ARI-0001 for ALL

Read More